This presentation will help guide nurses in the use of novel agents, the timing of those agents, and the treatment when a patient has progressed after first-line therapy. New agents will be discussed, including administration information, side effects, and helpful patient education information for nursing.

Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.

The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Outcomes of relapsed/refractory DLBCL differ based on the response to initial therapy, timing of relapse, and opportunity to undergo transplant. A multidisciplinary approach is required for appropriate patient selection and the management of acute toxicities to prevent fatal outcomes.

Clinicians are challenged to remain up-to-date with the recent advances in the management of early stage DLBCL, and education will help them to make informed decisions in their routine clinical practice.

These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of relapsed/refractory disease.

New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.

There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies.

CAR T-cell therapy represents a novel class of immunotherapy and its use has been expanding in relapsed or refractory hematologic malignancies. To ensure optimal patient outcomes, treatment-related toxicities must be closely monitored and quickly managed.

New promising combinations of chemoimmunotherapy with antibody drug conjugates, and small molecule inhibitors may offer an alternative approach for patients with relapsed or refractory disease. Many of these new therapies are oral and will be managed by a multidisciplinary team.